Organigram Global (OGI) Stock Price, News & Analysis

Company Overview

Organigram Global Inc. (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts. Organigram distributes under a variety of brands, including Monjour, Edison and First Growth, targeting diverse consumer segments from value-focused to premium. Its cultivation methods combine indoor and greenhouse systems with automated processes designed to ensure product consistency, safety and quality.

Organigram serves markets across Canada and has established partnerships to access select international markets in jurisdictions that recognize Canadian GMP certification. The company’s leadership team is led by Chief Executive Officer Greg Engel, who has guided Organigram through its public listings on the Toronto Stock Exchange and the Nasdaq in 2020. Under his management, Organigram has focused on innovation in product formats, efficiency in cultivation, and strategic brand development to navigate the evolving regulatory landscape.

Key Stats

• Today's Range: $1.36 to $1.39
• 50-Day Range: $1.25 to $1.59
• 52-Week Range: $1.11 to $2.24
• Volume: 617,734 shs
• Average Volume: 824,186 shs
• Market Capitalization: $191.45 million
• P/E Ratio: 9.71
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Organigram Global Stock Analysis - MarketRank™

Organigram Global scored higher than 25% of companies evaluated by MarketBeat, and ranked 751st out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Organigram Global has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Organigram Global has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: -60.00%

Earnings Growth

Earnings for Organigram Global are expected to decrease by -60.00% in the coming year, from $0.10 to $0.04 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organigram Global is 9.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organigram Global is 9.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.88.

Price to Book Value per Share Ratio

Organigram Global has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OGI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organigram Global does not currently pay a dividend.

Dividend Growth

Organigram Global does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.25

News Sentiment

Organigram Global has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Organigram Global this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for OGI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

8 people have added Organigram Global to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organigram Global insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.09% of the stock of Organigram Global is held by insiders.

Percentage Held by Institutions

34.63% of the stock of Organigram Global is held by institutions.

Company Calendar

• Last Earnings: 2/10/2026
• Today: 5/08/2026
• Next Earnings (Confirmed): 5/12/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OGI
• CIK: 1620737
• Web: www.organigram.ca
• Phone: (844) 644-4726
• Fax: N/A
• Employees: 1,139
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): $0.14
• Trailing P/E Ratio: 9.71
• Forward P/E Ratio: 13.60
• P/E Growth: N/A
• Net Income: -$17.70 million
• Net Margins: 6.03%
• Pretax Margin: 1.59%
• Return on Equity: -15.41%
• Return on Assets: -10.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.73
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $185.07 million
• Price / Sales: 1.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 140,770,000
• Free Float: 140,641,000
• Market Cap: $191.45 million
• Optionable: Optionable
• Beta: 1.50